Loading clinical trials...

SARS-CoV-2 Safety Study for the Treatment of COVID-19 | Clinical Trials | Clareo Health

WITHDRAWNPHASE2

SARS-CoV-2 Safety Study for the Treatment of COVID-19

NCT06489860•DHA Coffee Co., Ltd

Summary

SARS-CoV-2 produced strong pluripotent stem cells and brain cells to protect Telomere chromosomes to maintain Acid Deoxyribonucleic (ADN) Molecules.

Detailed Description

SARS-CoV-2 produced strong pluripotent stem cells and brain cells to change and disappear defective cells in virus variants, Covid-19 disease. Pluripotent stem cells produced strong cells serve as a repair system, replacing damaged cells, defective cells and dead cells. CHEMISTRY: SARS-CoV-2 does not use any chemicals, no colors and no additives and no preservatives. Toxicology: SARS-CoV-2 product is not adverse effect, non-toxic and no pharmacal toxicology. SARS-CoV-2 is not placebo drug

Eligibility

Age

1 - 130 years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•SARS-CoV-2

Key Dates

Start Date

January 28, 2025

Primary Completion Date

January 30, 2025

Completion Date

February 4, 2025

Last Updated

September 4, 2025

Conditions

SARS-CoV-2

Interventions

HIV

DRUG

Malignant Neoplasms Safety Study for the Treatment of Neoplasms

DRUG

Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Symptoms of Long COVID

NCT06631287

Long COVIDSars-CoV-2 Infection+2 more

View study

RECRUITINGPHASE1

T Cell Therapy Opposing Novel COVID-19 Infection in Immunocompromised Patients

NCT05141058

SARS-CoV-2 Infection

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: September 4, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

SARS-CoV-2 Safety Study for the Treatment of COVID-19

Inclusion Criteria

Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Symptoms of Long COVID

T Cell Therapy Opposing Novel COVID-19 Infection in Immunocompromised Patients

A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease

Clinical Outcomes and Pharmacotherapy Effectiveness in the VA Health Care System (COPE-VA)

A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age

COVID-19 - Study of the Kinetics of the Immune Response During the Intensive Care Unit Stay in Adult Patients Infected With SARS-CoV-2: Multicentric Non Interventional Study